Ratings Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
33.58 USD +0.18% Intraday chart for Harmony Biosciences Holdings, Inc. +0.09% +3.96%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's profit outlook over the next few years is a strong asset.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • With a P/E ratio at 11.22 for the current year and 8.36 for next year, earnings multiples are highly attractive compared with competitors.
  • The company has a low valuation given the cash flows generated by its activity.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
+3.96% 1.91B
C-
+33.46% 701B
C+
+26.24% 570B
B
+0.93% 381B
C+
+21.03% 334B
B-
+17.51% 322B
C+
+0.74% 209B
B+
+2.95% 212B
B-
-6.05% 205B
A+
-3.61% 157B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes